Clinical trial · Observational
Measurement of Circulating Tumor Cells in Prostate Cancer
NCT04101305CI-TRIAL-00040785ICELLATEPCunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Can tumor cells and tumor DNA be sampled from blood samples from prostate cancer patients? Is it possible to understand the causal relationship between the occurrence of the tumor cells and the tumor DNA in the blood by reviewing the patient's medical records, including information about investigations, analytical reports or diagnoses? Can gene defects that may be useful in predicting the best treatment be detected by sequencing individual tumor cells or plasma from blood samples?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IsoPic | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Localised prostate cancer
- description
- Patients diagnosed with prostate cancer of moderate estimated risk suitable for and scheduled for prostatectomy with gland evacuation
- interventionNames
- Diagnostic Test: IsoPic
- label
- Stage 3 prostate cancer
- description
- Patients with diagnosed stage 3 prostate cancer
- interventionNames
- Diagnostic Test: IsoPic
- label
- Stage 4 prostate cancer
- description
- Patients with diagnosed stage 4 prostate cancer
- interventionNames
- Diagnostic Test: IsoPic
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 125 Years
Show eligibility criteria text
Inclusion Criteria: * patients diagnosed with prostate cancer of moderate risk planned for prostatectomy with lymph node removal, or * patients diagnosed with prostate cancer stage 3, or * patients with diagnosed prostate cancer stage 4, or * patients with diagnosed benign inflammatory prostatitis or other benign urological condition constituting age-matched, cancer free, controls Exclusion Criteria: * Patients undergoing prostate cancer treatment (no prostate cancer treatment should be given to the patient before blood collection) * Patients with previous malignancy
References
Publications (3)
- BACKGROUNDCastro et al., Surgery Curr Res 2012, 2:3 http://dx.doi.org/10.4172/2161-1076.1000113
- BACKGROUNDCastro et al., J Integr Oncol 2018, 7:3 DOI: 10.4172/2329-6771.1000212
- BACKGROUNDCastro et al., Disease Markers Volume 2018, Article ID 4653109, 5 pages https://doi.org/10.1155/2018/4653109